Chapters

Transcript

Video

Ursula Matulonis, MD Shares Results of the SORAYA Study

Ursula Matulonis, MD presented results of the SORAYA study at the 2022 Society for Gynecologic Oncology Annual Meeting. The study examined the efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression.


Published

March 25, 2022

Created by

Dana-Farber

Related Presenters

Ursula Matulonis, MD

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Institute Physician
Professor of Medicine, Harvard Medical School

Ursula A. Matulonis, MD is Chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School.

View full profile